Effect of tunicamycin on Candida albicans biofilm formation and maintenance

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 473-479

  Pierce, Christopher G ^a   Thomas, Derek P ^a   López Ribot, José L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Candidiasis; Cell wall mannoproteins; Microbial communities; N glycosylation

Indexed keywords

MANNOPROTEIN; TUNICAMYCIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BIOFILM; CANDIDA ALBICANS; DEGLYCOSYLATION; FUNGUS GROWTH; GROWTH INHIBITION; MICROTITER PLATE ASSAY; PROTEOMICS;

BIOFILMS; CANDIDA ALBICANS; ENZYME INHIBITORS; FUNGAL PROTEINS; GLYCOSYLATION; HUMANS; MEMBRANE GLYCOPROTEINS; PROTEOME; TUNICAMYCIN;

EID: 60649094307     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn515     Document Type: Article

References (37)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51.
2. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
3. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
4. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol 2002; 19: 139-43.
5. Ramage G, Martinez JP, Lopez-Ribot JL. Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res 2006; 6: 979-86.
6. Ramage G, Saville SP, Thomas DP et al. Candida biofilms: An update. Eukaryot Cell 2005; 4: 633-8.
7. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-67.
8. Ramage G, VandeWalle K, Wickes BL et al. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-70.
9. Chandra J, McCormick TS, Imamura Y et al. Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun 2007; 75: 2612-20.
10. Kuo SC, Lampen JO. Tunicamycin - an inhibitor of yeast glycoprotein synthesis. Biochem Biophys Res Commun 1974; 58: 287-95.
11. Bates S, Hughes HB, Munro CA et al. Outer chain N-glycans are required for cell wall integrity and virulence of Candida albicans. J Biol Chem 2006; 281: 90-8.
12. Chaffin WL, Lopez-Ribot JL, Casanova M et al. Cell wall and secreted proteins of Candida albicans: Identification, function, and expression. Microbiol Mol Biol Rev 1998; 62: 130-80.
13. Ruiz-Herrera J, Elorza MV, Valentin E et al. Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res 2006; 6: 14-29.
14. Gow NA, Bates S, Brown AJ et al. Candida cell wall mannosylation: importance in host-fungus interaction and potential as a target for the development of antifungal drugs. Biochem Soc Trans 1999; 27: 512-6.
15. Thomas DP, Bachmann SP, Lopez-Ribot JL. Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics 2006; 6: 5795-804.
16. Casanova M, Lopez-Ribot JL, Monteagudo C et al. Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans. Infect Immun 1992; 60: 4221-9.
17. Gomez MJ, Torosantucci A, Arancia S et al. Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans. Infect Immun 1996; 64: 2577-84.
18. Ramage G, Vande Walle K, Wickes BL et al. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
19. Ramage G, Bachmann S, Patterson TF et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49 973-80.
20. Viudes A, Lazzell A, Perea S et al. The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett 2004; 232: 133-8.
21. Monteagudo C, Viudes A, Lazzell A et al. Tissue invasiveness and non-acidic pH in human candidiasis correlate with 'In vivo' expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. J Clin Pathol 2004; 57: 598-603.
22. Masuoka J, Hazen KC. Cell wall protein mannosylation determines Candida albicans cell surface hydrophobicity. Microbiology 1997; 143: 3015-21.
23. Murgui A, Elorza MV, Sentandreu R. Tunicamycin and papulacandin B inhibit incorporation of specific mannoproteins into the wall of Candida albicans regenerating protoplasts. Biochim Biophys Acta 1986; 884: 550-8.
24. Blankenship JR, Mitchell AP. How to build a biofilm: A fungal perspective. Curr Opin Microbiol 2006; 9: 588-94.
25. Nobile CJ, Mitchell AP. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr Biol 2005; 15: 1150-5.
26. Nobile CJ, Andes DR, Nett JE et al. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2006; 2: E63.
27. Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006; 8: 1382-91.
28. Nobile CJ, Mitchell AP. Microbial biofilms: E pluribus unum. Curr Biol 2007; 17: R349-R353.
29. Vespa MN, Lebecq JC. The morphology of Candida albicans in two different Earle base media in the presence of tunicamycin. Mycoses 1996; 39: 271-7.
30. Baillie GS, Douglas LJ. Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 1999; 48: 671-9.
31. Ramage G, VandeWalle K, Lopez-Ribot JL et al. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 2002; 214: 95-100.
32. Baillie GS, Douglas LJ. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol 1999; 310: 644-56.
33. Bachmann SP, VandeWalle K, Ramage G et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002; 46: 3591-6.
34. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
35. Green CB, Cheng G, Chandra J et al. RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology 2004; 150: 267-75.
36. Peltroche-Llacsahuanga H, Goyard S, d'Enfert C et al. Protein O-mannosyltransferase isoforms regulate biofilm formation in Candida albicans. Antimicrob Agents Chemother 2006; 50: 3488-91.
37. Nobile CJ, Nett JE, Andes DR et al. Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot Cell 2006; 5: 1604-10.